First Time Loading...
C

Cannassure Therapeutics Ltd
TASE:CSURE

Watchlist Manager
Cannassure Therapeutics Ltd
TASE:CSURE
Watchlist
Price: 1 610 ILS 6.55% Market Closed
Updated: May 10, 2024

Intrinsic Value

CSURE's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

CannAssure Therapeutics Ltd. engages in the cultivation, development, and distribution of medical cannabis products. [ Read More ]

The intrinsic value of one CSURE stock under the Base Case scenario is 222.13 ILS. Compared to the current market price of 1 610 ILS, Cannassure Therapeutics Ltd is Overvalued by 86%.

Key Points:
CSURE Intrinsic Value
Base Case
222.13 ILS
Overvaluation 86%
Intrinsic Value
Price
C
Worst Case
Base Case
Best Case

Valuation Backtest
Cannassure Therapeutics Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling CSURE stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Cannassure Therapeutics Ltd

Provide an overview of the primary business activities
of Cannassure Therapeutics Ltd.

What unique competitive advantages
does Cannassure Therapeutics Ltd hold over its rivals?

What risks and challenges
does Cannassure Therapeutics Ltd face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Cannassure Therapeutics Ltd.

Provide P/S
for Cannassure Therapeutics Ltd.

Provide P/E
for Cannassure Therapeutics Ltd.

Provide P/OCF
for Cannassure Therapeutics Ltd.

Provide P/FCFE
for Cannassure Therapeutics Ltd.

Provide P/B
for Cannassure Therapeutics Ltd.

Provide EV/S
for Cannassure Therapeutics Ltd.

Provide EV/GP
for Cannassure Therapeutics Ltd.

Provide EV/EBITDA
for Cannassure Therapeutics Ltd.

Provide EV/EBIT
for Cannassure Therapeutics Ltd.

Provide EV/OCF
for Cannassure Therapeutics Ltd.

Provide EV/FCFF
for Cannassure Therapeutics Ltd.

Provide EV/IC
for Cannassure Therapeutics Ltd.

Show me price targets
for Cannassure Therapeutics Ltd made by professional analysts.

Compare the intrinsic valuations
of Cannassure Therapeutics Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Cannassure Therapeutics Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Cannassure Therapeutics Ltd compared to its peers.

Compare the P/E ratios
of Cannassure Therapeutics Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Cannassure Therapeutics Ltd with its peers.

Analyze the financial leverage
of Cannassure Therapeutics Ltd compared to its main competitors.

Show all profitability ratios
for Cannassure Therapeutics Ltd.

Provide ROE
for Cannassure Therapeutics Ltd.

Provide ROA
for Cannassure Therapeutics Ltd.

Provide ROIC
for Cannassure Therapeutics Ltd.

Provide ROCE
for Cannassure Therapeutics Ltd.

Provide Gross Margin
for Cannassure Therapeutics Ltd.

Provide Operating Margin
for Cannassure Therapeutics Ltd.

Provide Net Margin
for Cannassure Therapeutics Ltd.

Provide FCF Margin
for Cannassure Therapeutics Ltd.

Show all solvency ratios
for Cannassure Therapeutics Ltd.

Provide D/E Ratio
for Cannassure Therapeutics Ltd.

Provide D/A Ratio
for Cannassure Therapeutics Ltd.

Provide Interest Coverage Ratio
for Cannassure Therapeutics Ltd.

Provide Altman Z-Score Ratio
for Cannassure Therapeutics Ltd.

Provide Quick Ratio
for Cannassure Therapeutics Ltd.

Provide Current Ratio
for Cannassure Therapeutics Ltd.

Provide Cash Ratio
for Cannassure Therapeutics Ltd.

What is the historical Revenue growth
over the last 5 years for Cannassure Therapeutics Ltd?

What is the historical Net Income growth
over the last 5 years for Cannassure Therapeutics Ltd?

What is the current Free Cash Flow
of Cannassure Therapeutics Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for Cannassure Therapeutics Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Cannassure Therapeutics Ltd

Current Assets 16.7m
Cash & Short-Term Investments 174k
Receivables 4.8m
Other Current Assets 11.8m
Non-Current Assets 23.9m
PP&E 22.9m
Intangibles 985k
Current Liabilities 25.8m
Accounts Payable 6.4m
Short-Term Debt 14m
Other Current Liabilities 5.3m
Non-Current Liabilities 16.2m
Long-Term Debt 16.2m
Other Non-Current Liabilities 22k
Efficiency

Earnings Waterfall
Cannassure Therapeutics Ltd

Revenue
33.8m ILS
Cost of Revenue
-30.5m ILS
Gross Profit
3.3m ILS
Operating Expenses
-6.1m ILS
Operating Income
-2.8m ILS
Other Expenses
-2.7m ILS
Net Income
-5.5m ILS

Free Cash Flow Analysis
Cannassure Therapeutics Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

CSURE Profitability Score
Profitability Due Diligence

Cannassure Therapeutics Ltd's profitability score is 41/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Exceptional ROE
Negative 1-Year Revenue Growth
Negative ROIC
41/100
Profitability
Score

Cannassure Therapeutics Ltd's profitability score is 41/100. The higher the profitability score, the more profitable the company is.

CSURE Solvency Score
Solvency Due Diligence

Cannassure Therapeutics Ltd's solvency score is 19/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Positive Net Debt
Short-Term Solvency
19/100
Solvency
Score

Cannassure Therapeutics Ltd's solvency score is 19/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CSURE Price Targets Summary
Cannassure Therapeutics Ltd

There are no price targets for CSURE.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

CSURE Price
Cannassure Therapeutics Ltd

1M 1M
+50%
6M 6M
+3 789%
1Y 1Y
+3 644%
3Y 3Y
+2 105%
5Y 5Y
+642%
10Y 10Y
+1 852%
Annual Price Range
1 610
52w Low
29.1
52w High
1 610
Price Metrics
Average Annual Return -18.51%
Standard Deviation of Annual Returns 45.79%
Max Drawdown -91%
Shares Statistics
Market Capitalization 123.9m ILS
Shares Outstanding 76 957
Percentage of Shares Shorted
N/A

CSURE Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Cannassure Therapeutics Ltd

Country

Israel

Industry

Pharmaceuticals

Market Cap

123.9m ILS

Dividend Yield

0%

Description

CannAssure Therapeutics Ltd. engages in the cultivation, development, and distribution of medical cannabis products. The firm has two main business activities; Yielding real estate and real estate investments in which the Company, directly and through its subsidiaries; locates, purchases, rents, upgrades and manages real estate. The firm and its subsidiaries have investments and property rights in Germany, Serbia, India, Kazakhstan, Latvia and Israel.

Contact

Ashdod
2 Hahadarim St.
+97288632111
http://www.cannassure.life/

IPO

1982-11-01

Employees

-

Officers

Founder & Chairman
Mr. Nir Peles C.P.A., CPA, M.B.A., MBA MA(Law)
VP of R&D
Dr. Hadile Ounallah-Saad

See Also

Discover More
What is the Intrinsic Value of one CSURE stock?

The intrinsic value of one CSURE stock under the Base Case scenario is 222.13 ILS.

Is CSURE stock undervalued or overvalued?

Compared to the current market price of 1 610 ILS, Cannassure Therapeutics Ltd is Overvalued by 86%.